These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 7618257)
1. Therapeutic effects of diethylcarbamazine and 3'-azido-3'-deoxythymidine on feline leukemia virus lymphoma formation. Nelson P; Sellon R; Novotney C; Devera C; Davidian M; English R; Tompkins M; Tompkins W Vet Immunol Immunopathol; 1995 May; 46(1-2):181-94. PubMed ID: 7618257 [TBL] [Abstract][Full Text] [Related]
2. Recombinant feline leukemia virus (FeLV) variants establish a limited infection with altered cell tropism in specific-pathogen-free cats in the absence of FeLV subgroup A helper virus. Bechtel MK; Hayes KA; Mathes LE; Pandey R; Stromberg PC; Roy-Burman P Vet Pathol; 1999 Mar; 36(2):91-9. PubMed ID: 10098636 [TBL] [Abstract][Full Text] [Related]
3. Effect of continuous oral diethylcarbamazine treatment on lymphocyte counts of feline leukemia virus-infected cats. Kitchen LW; Mather FJ; Cotter SM J Clin Lab Immunol; 1988 Dec; 27(4):179-81. PubMed ID: 2855080 [TBL] [Abstract][Full Text] [Related]
4. A trial with 3'-azido-2',3'-dideoxythymidine and human interferon-α in cats naturally infected with feline leukaemia virus. Stuetzer B; Brunner K; Lutz H; Hartmann K J Feline Med Surg; 2013 Aug; 15(8):667-71. PubMed ID: 23321692 [TBL] [Abstract][Full Text] [Related]
5. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus. Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009 [TBL] [Abstract][Full Text] [Related]
6. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine. Harbour DA; Gunn-Moore DA; Gruffydd-Jones TJ; Caney SM; Bradshaw J; Jarrett O; Wiseman A Vaccine; 2002 Jul; 20(23-24):2866-72. PubMed ID: 12126896 [TBL] [Abstract][Full Text] [Related]
7. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). Zeidner NS; Rose LM; Mathiason-DuBard CK; Myles MH; Hill DL; Mullins JI; Hoover EA J Acquir Immune Defic Syndr (1988); 1990; 3(8):787-96. PubMed ID: 2164083 [TBL] [Abstract][Full Text] [Related]
8. No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus. Helfer-Hungerbuehler AK; Spiri AM; Riond B; Grest P; Boretti FS; Hofmann-Lehmann R Vaccine; 2015 Mar; 33(13):1578-85. PubMed ID: 25698488 [TBL] [Abstract][Full Text] [Related]
9. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Hartmann K; Donath A; Beer B; Egberink HF; Horzinek MC; Lutz H; Hoffmann-Fezer G; Thum I; Thefeld S Vet Immunol Immunopathol; 1992 Dec; 35(1-2):167-75. PubMed ID: 1363008 [TBL] [Abstract][Full Text] [Related]
10. Effects of a 98% solution of glycerol or sterilization with ethylene oxide on FeLV in bone allografts and effects on bone incorporation of allografts in cats. Coronado GS; Swenson CL; Martinez SA; Burkhardt KS; Arnoczky SP Am J Vet Res; 2000 Jun; 61(6):665-71. PubMed ID: 10850843 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study. Lafrado LJ J Am Vet Med Assoc; 1994 Mar; 204(6):914-7. PubMed ID: 8188511 [TBL] [Abstract][Full Text] [Related]
12. Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection. Major A; Cattori V; Boenzli E; Riond B; Ossent P; Meli ML; Hofmann-Lehmann R; Lutz H Vet Res; 2010; 41(2):17. PubMed ID: 19861115 [TBL] [Abstract][Full Text] [Related]
13. Detection of antibodies to the feline leukemia Virus (FeLV) transmembrane protein p15E: an alternative approach for serological FeLV detection based on antibodies to p15E. Boenzli E; Hadorn M; Hartnack S; Huder J; Hofmann-Lehmann R; Lutz H J Clin Microbiol; 2014 Jun; 52(6):2046-52. PubMed ID: 24696026 [TBL] [Abstract][Full Text] [Related]
14. Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Mathes LE; Polas PJ; Hayes KA; Swenson CL; Johnson S; Kociba GJ Antimicrob Agents Chemother; 1992 Dec; 36(12):2715-21. PubMed ID: 1336345 [TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy in cats progressively infected with feline leukaemia virus: lessons from a series of 18 consecutive cases from Australia. Westman ME; Hall E; Norris JM; Meili T; Hofmann-Lehmann R; Malik R Aust Vet J; 2024 Sep; 102(9):453-465. PubMed ID: 39042044 [TBL] [Abstract][Full Text] [Related]
16. Hematologic effects of short-term oral diethylcarbamazine treatment given to chronically feline leukemia virus-infected cats. Kitchen LW; Mather FJ Cancer Lett; 1989 Jun; 45(3):183-7. PubMed ID: 2543497 [TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression. Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M Clin Vaccine Immunol; 2015 Jul; 22(7):798-805. PubMed ID: 25972402 [TBL] [Abstract][Full Text] [Related]
18. Comparison of three feline leukaemia virus (FeLV) point-of-care antigen test kits using blood and saliva. Westman ME; Malik R; Hall E; Sheehy PA; Norris JM Comp Immunol Microbiol Infect Dis; 2017 Feb; 50():88-96. PubMed ID: 28131385 [TBL] [Abstract][Full Text] [Related]